back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-04-17 20:30 Tx date 2024-04-16 |
$WOLF
Grey Wolf Animal Health Corp. (formerly Magen Ventures I Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$14,600
+20,000 vol $0.73 each |
235,000 | |
| Filed 2022-11-16 18:23 Tx date 2022-11-15 |
$MAGNP
Grey Wolf Animal Health Corp. (formerly Magen Ventures I Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
215,000 | ||
| Filed 2022-11-16 18:22 Tx date 2022-11-15 |
$MAGNP
Grey Wolf Animal Health Corp. (formerly Magen Ventures I Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
232,162 | ||
| Filed 2022-05-19 21:55 Tx date 2022-05-18 |
$MRV
Nuvo Pharmaceuticals Inc. (d/b/a Miravo Healthcare) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Deferred Share Unit Plan (DSU)
56 - Grant of rights
|
+12,113 vol |
19,793 | |
| Filed 2021-05-21 12:13 Tx date 2021-05-20 |
$MRV
Nuvo Pharmaceuticals Inc. (d/b/a Miravo Healthcare) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Deferred Share Unit Plan (DSU)
56 - Grant of rights
|
+7,680 vol |
7,680 | |
| Filed 2021-05-21 12:12 Tx date 2017-05-11 |
$MRV
Nuvo Pharmaceuticals Inc. (d/b/a Miravo Healthcare) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Deferred Share Unit Plan (DSU)
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-07-02 09:51 Tx date 2020-06-30 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,530
+7,000 vol $0.79 each |
75,000 | |
| Filed 2020-06-11 13:58 Tx date 2020-06-10 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,340
+3,000 vol $0.78 each |
68,000 | |
| Filed 2020-06-10 14:07 Tx date 2020-03-13 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,120
+2,000 vol $0.56 each |
36,000 | |
| Filed 2020-06-10 10:34 Tx date 2020-06-05 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$6,304
+8,000 vol $0.79 each |
63,000 | |
| Filed 2020-05-19 15:04 Tx date 2020-05-14 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,650
+5,000 vol $0.73 each |
55,000 | |
| Filed 2020-05-19 15:02 Tx date 2020-05-14 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,000
+10,000 vol $0.70 each |
50,000 | |
| Filed 2020-05-14 13:54 Tx date 2020-05-13 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+7,000 vol |
110,655 | |
| Filed 2020-03-25 18:12 Tx date 2020-03-25 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,200
+2,000 vol $0.60 each |
40,000 | |
| Filed 2020-03-25 18:12 Tx date 2020-03-25 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,320
+4,000 vol $0.58 each |
38,000 | |
| Filed 2020-03-06 16:19 Tx date 2020-03-05 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$840.00
+1,000 vol $0.84 each |
34,000 | |
| Filed 2020-03-06 16:18 Tx date 2020-03-05 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,075
+2,500 vol $0.83 each |
33,000 | |
| Filed 2020-03-06 16:18 Tx date 2020-03-05 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,645
+4,500 vol $0.81 each |
30,500 | |
| Filed 2020-03-06 16:16 Tx date 2020-03-05 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,600
+2,000 vol $0.80 each |
26,000 | |
| Filed 2020-03-06 16:10 Tx date 2020-03-04 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,880
+4,000 vol $0.97 each |
24,000 |